Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Floorless Preferred Stock/Debenture -- Ignore unavailable to you. Want to Upgrade?

To: marketmover who wrote (1043)	11/20/1999 7:57:00 AM
From: OpusX	Respond to of 1438

?????????????????????????

To: marketmover who wrote (1043)	11/20/1999 9:31:00 AM
From: DanZ	Read Replies (1) \| Respond to of 1438

marketmover, Based on your previous posts on GUMM, and in particular Message 11824226, I assume that you are still trying to convince the uniformed that the Citadel financing is a spiral convert. You are wrong. You may also be unaware that Gum Tech redeemed 20% of the convertible notes ($800,000) and 20% of the preferred stock ($400,000) in the third quarter 99. This was reported in the 10Q that came out last Monday. Gum Tech redeemed some of the principal early in exchange for a waiver because their gum sales in Q3 were below the threshold specified in a loan covenant. They conformed to the other two loan covenants (EBITDA and cash balance). Gum Tech issued 117,759 shares at 11.21 per share to redeem the principal and Citadel sold the stock in September before the recent rally. A "wreck" is more likely to occur to people who buy and sell securities that they don't know anything about. You might educate yourself by reading the following posts on this thread. Message 11827742 Message 11833856 Message 11834674 Message 11836041 Message 11836490 BTW, Zicam is selling very well, as evidenced by Message 11988958 The lawsuit filed by Quigley is completely without merit because the Eby patent only protects them for zinc delivered to the oral mucosa. Considering your lack of due diligence on the Citadel financing, you might not know that Zicam is a nasal product. Two patent attorneys working independently of each other before Zicam was launched opined that Gum Tech did not infringe on the Eby patent. You can read the patent at 164.195.100.11 . Only the claims offer legal protection against infringement. The abstract and description do NOT offer legal protection against infringement. Also, the RE in the patent number means reissue, and if you read the patent that it replaces, RE33,465 is much narrower in scope than the original patent. The Patent Office forced Eby to narrow the scope of his patent to oral deliver only and nasal delivery was removed from the original patent. This alone provides Gum Tech a very strong case if Quigley pursues their frivolous lawsuit. News about the lawsuit caused some shareholders to panic last Thursday, but IMO, that was the last opportunity to buy the stock below 16. The only possible exception is if Quigley somehow convinces the judge to grant a temporary restraining order that would prevent Gum Tech from selling Zicam. You can read messages.yahoo.com for information on the process. The odds of Quigley getting a TRO are slim to none. There is a lot of information in this post, but I would assume that somebody who plunked down 5,000 shares on a short position would want to know what he shorted...unless of course you are just gambling with ~ $100,000. BTW, regarding Message 11819755 ... Based on the lack of information in this post, I would have to say the post is a sack of s@#&t. Regards, Dan